Norgine warns of unintended cost of UK generic switching

A proposal to encourage generic drug switching at the pharmacy could lead to some treatment costs rising as an unintended consequence of the reformed Pharmaceutical Price Regulation Scheme, which was recently announced by the UK government and the Association of the British Pharmaceutical Industry (Marketletter November 24). The warning was issued by Peter Martin, the chief operating officer of Netherlands-headquartered Norgine, a specialty drugmaker which resigned from the ABPI in October over the latter's negotiating stance (Marketletter October 13).